Adipose Tissue Derived Mesenchymal Stromal/Stem Cells is under clinical development by Cell2Cure and currently in Phase II for Keratoconjunctivitis Sicca (Dry Eye). According to GlobalData, Phase II drugs for Keratoconjunctivitis Sicca (Dry Eye) have a 56% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how Adipose Tissue Derived Mesenchymal Stromal/Stem Cells’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Adipose Tissue Derived Mesenchymal Stromal/Stem Cells overview
Cell therapy is under development for the treatment of corneal transplant, diabetic foot ulcer, dry eye disease, lung transplant rejection, Sjogren’s syndrome and Xerostomia. The therapeutic candidate comprises of adipose tissue derived mesenchymal stromal or stem cells. It is administered through subcutaneous route.
Cell2Cure is a biotherapeutic company developing ‘off-the-shelf’ adipose tissue derived mesenchymal stromal cell (ASC) products applied in a wide range of advanced-stage diseases with involvement of inflammation and immunological activity, blood circulatory disturbance, fibrosis and scar development. Cell2Cure is headquartered in Birkerod, Denmark.
For a complete picture of Adipose Tissue Derived Mesenchymal Stromal/Stem Cells’s drug-specific PTSR and LoA scores, buy the report here.